Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. [electronic resource]
Producer: 20120516Description: 1153-9 p. digitalISSN:- 1532-1827
- Angiogenesis Inhibitors -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- blood
- Carboplatin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- blood
- Clinical Trials, Phase III as Topic
- Deoxycytidine -- administration & dosage
- Etoposide -- administration & dosage
- Female
- Fibroblast Growth Factor 2 -- blood
- Humans
- Intercellular Adhesion Molecule-1 -- blood
- Interleukin-8 -- blood
- Lung Neoplasms -- blood
- Male
- Middle Aged
- Multicenter Studies as Topic
- Multivariate Analysis
- Neovascularization, Pathologic -- blood
- Proportional Hazards Models
- Randomized Controlled Trials as Topic
- Small Cell Lung Carcinoma -- blood
- Survival Analysis
- Thalidomide -- therapeutic use
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- blood
- Gemcitabine
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.